Stocks · News reference

8-K filing — UTAH MEDICAL PRODUCTS INC (UTMD)

Aug 31, 2026, 5:33 PMSEC EDGAR

Filed: 2026-08-31 AccNo: 0001096906-26-001326 Size: 149 KB Item 7.01: Regulation FD Disclosure

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Zacks Investment ResearchOct 8, 2026, 5:02 PMNa
UTMD Trades at a Premium to the Industry: How to Play the Stock?
Utah Medical Products (UTMD) trades at a premium valuation of 4.05X EV/sales versus industry average of 2.68X. While the company benefits from strong margins (58.2% gross margin), a debt-free balance sheet with $87.5M in cash, and strategic acquisitions, it faces near-term headwinds including 12.3% revenue decline, major customer losses, and projected 10-13% revenue decline for 2026. Long-term investors may hold, but new investors should await a better entry point.
UTMD EOLS CGC
BenzingaSep 15, 2026, 2:03 PMBenzinga Newsdesk
Utah Medical Products Announces Tender Offer To Repurchase Up To 650,000 Share At $75.00/Share; Offer To Commence September 22
UTMD
BenzingaJul 23, 2026, 1:08 PMBenzinga Newsdesk
Utah Medical Products Q2 EPS $0.84 Down From $0.94 YoY, Sales $8.529M Down From $9.953M YoY
Utah Medical Products (NASDAQ:UTMD) reported quarterly earnings of $0.84 per share. This is a 10.64 percent decrease over earnings of $0.94 per share from the same period last year. The company reported $8.529 million
UTMD